Page 25 - ARNM-3-1

Advances in Radiotherapy &

Nuclear Medicine

REVIEW ARTICLE
Treatment consensus for locally advanced

cervical cancer

Ping Jiang , Zhuhui Yuan , Lichun Wei , Fengju Zhao , Xiangkun Yuan ,
2
1†
1†
3
4
5
8
Yipeng Song , Jing Bai , Xiaofan Li , Baosheng Sun , Lijuan Zou , Sha Li ,
10
7
9
6
Yuhua Gao , Yanhong Zhuo , Song Gao , Qin Xu , Xiaohong Zhou ,
14
15
13
11
12
16
Hong Zhu , Yunyan Zhang * , Zi Liu * , and Junjie Wang *
17
1
18
1 Department of Radiation Oncology, Cancer Center of Peking University Third Hospital, Peking
University Third Hospital, Haidian District, Beijing, China
2 Department of Radiotherapy, Xijing Hospital, The Fourth Military Medical University of People’s
Liberation Army, Xi’an, Shaanxi, China
3 Radiotherapy Center, Gansu Province Maternal and Child Health Hospital/Gansu Province Central
Hospital, Lanzhou, Gansu, China
4 Department of Radiation Oncology, Hebei Cangzhou Integrated Traditional Chinese and Western
Medicine Hospital, China
5 Department of Oncology, Yantai Yuhuangding Hospital, Yantai, China
6 Department of Radiation Oncology, Baotou Tumor Hospital, Baotou, China
7 Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China
8 Department of Radiotherapy, Jilin Province Cancer Hospital, Changchun, China
† These authors contributed equally 9 The Second Hospital Affiliated to Dalian Medical University, Dalian, China
to this work. 10 Department of Radiation Oncology, 940 Hospital of the Joint Logistics Support Force of The
*Corresponding authors: Chinese People’s Liberation Army, Lanzhou, Gansu, China
Yunyan Zhang
(Zhangyunyan_1972@163.com)
Zi Liu
(liuzmail@163.com)
Junjie Wang Abstract
(junjiewang@pku.edu.cn)
Concurrent chemoradiotherapy (CCRT) involves the simultaneous administration
Citation: Jiang P, Yuan Z, Wei L,
et al. Treatment consensus of chemotherapy and radiotherapy, in which low-dose chemotherapy enhances the
for locally advanced cervical effectiveness of radiotherapy. This combined approach mitigates tumor recurrence
cancer. Adv Radiother Nucl Med. and metastasis, ultimately improving patient prognosis. The primary mechanism
2025;3(1):17-27.
doi: 10.36922/arnm.4032 behind the increased radiosensitivity induced by concurrent chemotherapy involves
inhibiting tumor cell repair and the complementary effects of chemotherapy and
Received: June 24, 2024
radiotherapy on different phases of the cell cycle. Despite CCRT application in patients
Revised: November 23, 2024 with locally advanced cervical cancer (LACC), the 5-year survival rate remains at
Accepted: December 17, 2024 60%. To improve treatment efficacy, a series of exploratory investigations have been
conducted, encompassing the integration of targeted therapy, immunotherapy,
Published online: January 13, and utilization of immunomodulatory agents in neoadjuvant protocols preceding
2025
CCRT. Although targeted therapies and immunomodulators represent efficacious
Copyright: © 2025 Author(s). interventions for LACC management, the scarcity of robust, large-scale evidence-
This is an Open-Access article
distributed under the terms of the based data necessitates the undertaking of multicenter prospective randomized Phase
Creative Commons Attribution III clinical trials and dissemination of high-quality publications to elevate the standard
License, permitting distribution, of evidence-based medicine. This consensus acts as a valuable resource for clinicians
and reproduction in any medium, and researchers, highlighting recent seminal evidence-based studies and the evolving
provided the original work is
properly cited. landscape of clinical research on targeted and immunomodulatory agents.
Publisher’s Note: AccScience
Publishing remains neutral with Keywords: Immunotherapy; Targeted therapy; Concurrent chemoradiotherapy; Locally
regard to jurisdictional claims in
published maps and institutional advanced cervical cancer
affiliations
Volume 3 Issue 1 (2025) 17 doi: 10.36922/arnm.4032